

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

## EQA round: TM3/18 - Tumour Markers

Dead line: 07.08.2018

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability												
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(180) CA 125</b>					15							15	15	100%
Samples and groups	[kU/L]													
<b>Sample A</b>		13,9	2,5	18	15							15	15	100%
(4) LIA (CLIA, CMIA, ECLIA); (1)	Abbott	15,9	0,59	3,7	6	0	CVPG	15,7	0,24	20%	12,5	18,9	6	
Other					9	0							9	
								3x 4/12, 2x 4/60, 2x 4/149, 2x 4/179						
<b>Sample B</b>		50,3	12	25	15							15	15	100%
(4) LIA (CLIA, CMIA, ECLIA); (1)	Abbott	56,1	2,1	3,8	6	0	CVPG	56,6	0,69	20%	45,2	68	6	
Other					9	0							9	
								3x 4/12, 2x 4/60, 2x 4/149, 2x 4/179						
<b>(181) CA 15-3</b>					14							14	13	93%
Samples and groups	[kU/L]													
<b>Sample A</b>		27,4	2,5	9,1	14							14	14	100%
(4) LIA (CLIA, CMIA, ECLIA); (1)	Abbott	28,0	2,4	8,8	6	0	CVPG	27,1	0,45	18%	22,2	32	6	
Other					8	0							8	
								2x 4/12, 2x 4/60, 2x 4/149, 2x 4/179						
<b>Sample B</b>		12,2	1,4	12	14							14	13	93%
(4) LIA (CLIA, CMIA, ECLIA); (1)	Abbott	12,0	0,96	8,1	6	0	CVPG	11,5	0,22	18%	9,43	13,6	6	
Other					8	0							8	
								2x 4/12, 2x 4/60, 2x 4/149, 2x 4/179						
<b>(182) CA 19-9</b>					15							15	13	87%
Samples and groups	[kU/L]													
<b>Sample A</b>		237	230	99	15							15	13	87%
(4) LIA (CLIA, CMIA, ECLIA); (1)	Abbott	509	35	6,8	5	0	CVPG	487	12	20%	389	585	5	
Other					10	0							10	
								4x 4/12, 2x 4/60, 2x 4/149, 2x 4/179						
<b>Sample B</b>		80,9	74	91	15							15	15	100%
(4) LIA (CLIA, CMIA, ECLIA); (1)	Abbott	168	18	10	5	0	CVPG	163	4,6	20%	130	196	5	
Other					10	0							10	
								4x 4/12, 2x 4/60, 2x 4/149, 2x 4/179						
<b>(183) CA 72-4</b>					16							15	14	93%
Samples and groups	[kU/L]													
<b>Sample A</b>		3,10	0,32	10	16							15	14	93%
(4) LIA (CLIA, CMIA, ECLIA); (60)	Roche	3,06	0,28	9,1	15	0	CVPG	3,18	0,057	20%	2,54	3,82	15	
Other					1	0							0	
								1x 1/185						
<b>Sample B</b>		5,45	0,55	10	16							15	15	100%
(4) LIA (CLIA, CMIA, ECLIA); (60)	Roche	5,40	0,51	9,5	15	0	CVPG	5,56	0,087	20%	4,44	6,68	15	
Other					1	0							0	
								1x 1/185						
<b>(184) CYFRA 21-1</b>					13							13	12	92%
Samples and groups	[µg/L]													
<b>Sample A</b>		10,3	0,94	9,1	13							13	13	100%
(4) LIA (CLIA, CMIA, ECLIA); (1)	Abbott	9,81	0,14	1,4	5	0	CVPG	10	0,33	18%	8,2	11,8	5	
(4) LIA (CLIA, CMIA, ECLIA); (60)	Roche	10,7	1,4	13	8	0	CVPG	10,2	0,15	18%	8,36	12,1	8	
<b>Sample B</b>		8,14	0,89	11	13							13	12	92%
(4) LIA (CLIA, CMIA, ECLIA); (1)	Abbott	7,49	0,38	5,1	5	0	CVPG	7,65	0,32	18%	6,27	9,03	5	
(4) LIA (CLIA, CMIA, ECLIA); (60)	Roche	8,57	1,0	12	8	0	CVPG	8,17	0,11	18%	6,69	9,65	8	
<b>(185) AFP</b>					15							15	14	93%
Samples and groups	[µg/L]													
<b>Sample A</b>		36,6	5,2	14	15							15	14	93%
Other					15	0							15	
								4x 4/1, 4x 4/12, 3x 4/60, 2x 4/149, 2x 4/179						
<b>Sample B</b>		16,8	1,9	12	15							15	14	93%
Other					15	0							15	
								4x 4/1, 4x 4/12, 3x 4/60, 2x 4/149, 2x 4/179						
<b>(186) hCG</b>					15							15	14	93%
Samples and groups	[U/L]													
<b>Sample A</b>		12,4	1,2	9,5	15							15	15	100%

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

## EQA round: TM3/18 - Tumour Markers

Dead line: 07.08.2018

Test	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability						N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL				
<b>(186) hCG</b>					15								15	14	93%
Samples and groups	[U/L]														
<b>Sample A</b>		12,4	1,2	9,5	15								15	15	100%
Other					15	0							15		
							2x 4/1, 3x 4/12, 3x 4/60, 2x 4/149, 2x 4/179, 3x 4/210								
<b>Sample B</b>		2,16	0,66	31	15								15	14	93%
Other					15	0							15		
							2x 4/1, 3x 4/12, 3x 4/60, 2x 4/149, 2x 4/179, 3x 4/210								
<b>(189) CEA</b>					15								15	15	100%
Samples and groups	[µg/L]														
<b>Sample A</b>		5,42	0,67	12	15								15	15	100%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		5,91	0,089	1,5	5	0	CVPG	5,99	0,076	16%	5,03	6,95	5		
Other					10	0							10		
							4x 4/12, 2x 4/60, 2x 4/149, 2x 4/179								
<b>Sample B</b>		30,3	2,9	9,7	15								15	15	100%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		31,7	0,55	1,7	5	0	CVPG	33	0,38	16%	27,7	38,3	5		
Other					10	0							10		
							4x 4/12, 2x 4/60, 2x 4/149, 2x 4/179								
<b>(191) PSA</b>					14								14	14	100%
Samples and groups	[µg/L]														
<b>Sample A</b>		6,90	1,3	18	14								14	14	100%
Other					14	0							14		
							4x 4/1, 3x 4/12, 2x 4/60, 2x 4/149, 2x 4/179, 1x 4/195								
<b>Sample B</b>		2,45	0,46	19	14								14	14	100%
Other					14	0							14		
							4x 4/1, 3x 4/12, 2x 4/60, 2x 4/149, 2x 4/179, 1x 4/195								
<b>(194) NSE</b>					13								13	11	85%
Samples and groups	[µg/L]														
<b>Sample A</b>		7,90	0,96	12	13								13	13	100%
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		7,74	0,78	10	12	0	CVPG	7,8	0,11	30%	5,46	10,2	12		
Other					1	0							1		
							1x 3/24								
<b>Sample B</b>		7,33	1,3	18	13								13	11	85%
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		7,51	1,1	15	12	0	CVPG	7,43	0,11	30%	5,2	9,66	12		
Other					1	0							1		
							1x 3/24								
<b>(195) SCCA</b>					9								9	7	78%
Samples and groups	[µg/L]														
<b>Sample A</b>		4,08	0,33	8,0	9								9	8	89%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		4,35	0,37	8,5	5	0	CVPG	4,15	0,088	23%	3,19	5,11	5		
Other					4	0							4		
							1x 3/24, 3x 4/60								
<b>Sample B</b>		1,65	0,22	13	9								9	7	78%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		1,65	0,22	13	5	0	CVPG	1,59	0,037	±0,7	0,89	2,29	5		
Other					4	0							4		
							1x 3/24, 3x 4/60								
<b>(198) free-PSA</b>					12								12	12	100%
Samples and groups	[µg/L]														
<b>Sample A</b>		5,84	0,57	9,8	12								12	12	100%
Other					12	0							12		
							4x 4/1, 2x 4/12, 2x 4/60, 2x 4/149, 1x 4/179, 1x 4/195								
<b>Sample B</b>		2,02	0,16	7,7	12								12	12	100%
Other					12	0							12		
							4x 4/1, 2x 4/12, 2x 4/60, 2x 4/149, 1x 4/179, 1x 4/195								
<b>(201) S-100</b>					8								7	7	100%
Samples and groups	[µg/L]														
<b>Sample A</b>		0,035	0,008	25	8								7	7	100%
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		0,032	0,003	12	7	0	CVPG	0,033		0 ± 0,013	0,02	0,046	7		
Other					1	0							0		
							1x 2/98								
<b>Sample B</b>		0,037	0,01	28	8								7	7	100%
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		0,034	0,005	17	7	0	CVPG	0,036		0 ± 0,013	0,023	0,049	7		
Other					1	0							0		
							1x 2/98								
<b>(206) Calcitonin</b>					5								4	4	100%
Samples and groups	[ng/L]														
<b>Sample A</b>		8,19	0,13	1,6	5								4	4	100%
Other					5	0							4		
							1x 1/24, 3x 4/29, 1x 4/60								
<b>Sample B</b>		18,6	1,4	7,3	5								4	4	100%

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

## EQA round: TM3/18 - Tumour Markers

Dead line: 07.08.2018

Test	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability							
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(206) Calcitonin</b>					5							4	4	100%
Samples and groups	[ng/L]													
<b>Sample A</b>		18,6	1,4	7,3	5							4	4	100%
Other					5	0						4		
							1x 1/24, 3x 4/29, 1x 4/60							
<b>(207) Thyreoglobulin</b>					5							5	5	100%
Samples and groups	[µg/L]													
<b>Sample A</b>		6,80	6,1	89	5							5	5	100%
Other					5	0						5		
							1x 3/24, 2x 4/29, 2x 4/60							
<b>Sample B</b>		13,7	6,7	49	5							5	5	100%
Other					5	0						5		
							1x 3/24, 2x 4/29, 2x 4/60							
<b>(208) beta-2-microglobulin</b>					10							8	8	100%
Samples and groups	[mg/L]													
<b>Sample A</b>		2,96	0,38	13	10							8	8	100%
Other					10	0						8		
							1x 1/36, 1x 4/29, 1x 6/1, 1x 6/58, 1x 6/75, 1x 6/91, 4x 6/149							
<b>Sample B</b>		4,21	0,43	10	10							8	8	100%
Other					10	0						8		
							1x 1/36, 1x 4/29, 1x 6/1, 1x 6/58, 1x 6/75, 1x 6/91, 4x 6/149							
<b>(205) Chromogranin A</b>					1							1	1	100%
Samples and groups	[µg/L]													
<b>Sample A</b>		92,8			1							1	1	100%
Other					1	0						1		
							1x 3/24							
<b>Sample B</b>		115			1							1	1	100%
Other					1	0						1		
							1x 3/24							

st\_kn\_p

End of report

Printed: 19.08.2018